公开(公告)号：EP1378247A4

公开(公告)日：2007-07-25

申请号：EP02717107

申请日：2002-04-11

申请人： SENJU PHARMA CO ,  MITSUBISHI PHARMA CORP

发明人： TAKAYAMA YOSHIKO ,  YOSHIDA YUKUO ,  UEHATA MASAYOSHI

IPC分类号： A61K45/00 ,  A61K31/00 ,  A61K31/16 ,  A61K31/337 ,  A61K31/415 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61P25/00 ,  A61P27/02 ,  A61P43/00 ,  C07D211/00 ,  C07D213/75 ,  C07D213/79 ,  C07D213/82 ,  C07D213/89 ,  C07D231/40 ,  C07D237/20 ,  C07D239/42 ,  C07D471/04

CPC分类号： C07D471/04 ,  A61K9/0048 ,  A61K31/00 ,  A61K31/437 ,  C07D211/00

摘要： Visual function improving agents containing compounds having an Rho kinase inhibitory activity, in particular (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as the active ingredient. Because of having effects of promoting axon extension in retinal gangliocytes and promoting regeneration of optic nerve cells, these agents are useful in treating visual function errors in association with various eye diseases caused by damage, defect, degeneration, etc. in retina and optic nerve.

公开(公告)号：EP1174150A4

公开(公告)日：2004-06-16

申请号：EP00919153

申请日：2000-04-21

申请人： MITSUBISHI PHARMA CORP

发明人： KAI HISASHI ,  UEHATA MASAYOSHI

IPC分类号： A61K31/00 ,  A61K31/437 ,  A61K31/4409 ,  C07D213/75 ,  C07D213/81 ,  A61K45/00

CPC分类号： C07D213/75 ,  A61K31/00 ,  A61K31/437 ,  A61K31/4409 ,  C07D213/81

摘要： Preventives/remedies for angiostenosis which contain compounds having an Rho kinase inhibitory activity. Compounds having an Rho kinase inhibitory activity such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane have various effects of suppressing the proliferation of endometrium regenerated after vascular lesion and the like. Owing to these effects, the above compounds are useful as preventives/remedies for angiostenosis, more particularly, angiostenosis induced by vascular wall lesion (for example, angiorestenosis following percutaneous coronary arterioplasty, angiorestenosis following percutaneous arterioplasty, angiostenosis following revascularization by indwelling a DCA or a stent, and angiostenosis following organ transplantation).

公开(公告)号：EP1034793A4

公开(公告)日：2003-07-09

申请号：EP99937073

申请日：1999-08-13

申请人： SENJU PHARMA CO ,  MITSUBISHI PHARMA CORP

发明人： AZUMA MITSUYOSHI ,  YOSHIDA YUKUO ,  WAKI MITSUNORI ,  UEHATA MASAYOSHI

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/00 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/551 ,  A61K45/00 ,  A61P27/02 ,  A61P27/06 ,  A61P27/10 ,  A61P43/00 ,  C07D471/04 ,  A61K31/445

CPC分类号： A61K31/551 ,  A61K31/00 ,  A61K31/437 ,  A61K31/4409 ,  A61K31/4545 ,  A61K31/496 ,  Y10S514/912 ,  Y10S514/913

摘要： Preventives/remedies for glaucoma containing compounds having an Rho kinase inhibitory activity, in particular, those represented by general formula (I), wherein each symbol is as defined in the specification. These preventives/remedies are novel ones having effects of lowering ocular tension, ameliorating optic papilla blood flow and promoting humor aqueous outflow.

公开(公告)号：EP1270570A4

公开(公告)日：2004-02-18

申请号：EP01912460

申请日：2001-03-16

申请人： MITSUBISHI PHARMA CORP

发明人： TAKANASHI SHINICHI ,  NAITO YOICHIRO ,  TANAKA HIROSHI ,  UEHATA MASAYOSHI ,  KATAYAMA KOSHIRO

IPC分类号： A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P15/06 ,  A61P15/10 ,  A61P15/18 ,  A61P19/00 ,  A61P19/10 ,  A61P25/00 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/06 ,  C07D213/75 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04 ,  A61K31/437 ,  A61K31/55 ,  C07D401/12

CPC分类号： C07D213/75 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

摘要： Amide compounds represented by the following general formula (I), isomers thereof or pharmaceutically acceptable salts of the same; wherein R1 represents hydrogen etc.; R2 represents hydrogen, etc.; X represents SO¿2?, etc.; Y represents a group of the formula (III), etc.; and a is 2. These compounds exhibit a remarkable and selective Rho kinase inhibitory effect without any troublesome toxicity and are excellent in oral absorbability, pharmacokinetics (drug absorption, distribution, metabolism, excretion, etc.) and physical properties (stability, etc.) as the compounds per se. Owing to these characteristics, these compounds are useful as remedies for various diseases in which Rho kinase participates.

公开(公告)号：EP1177796A4

公开(公告)日：2003-11-19

申请号：EP00921077

申请日：2000-04-27

申请人： MITSUBISHI PHARMA CORP

发明人： NAKAMUTA MAKOTO ,  NAWATA HAJIME ,  UEHATA MASAYOSHI

IPC分类号： A61K31/16 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4409 ,  A61P1/16 ,  A61P29/00 ,  A61P35/00 ,  C07D213/75 ,  C07D471/04 ,  A61K45/00 ,  A61K31/27 ,  A61K31/415 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/445

CPC分类号： C07D471/04 ,  A61K31/16 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4409 ,  C07D213/75

摘要： Preventives/remedies for liver diseases which contain compounds having an Rho kinase inhibitory activity; and liver astrocyte activation inhibitors. Because of having excellent effects of inhibiting the activation of liver astrocytes, preventing the fibrosis of liver tissues, etc., compounds having an Rho kinase inhibitory activity (for example, (+)- trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl) cyclohexane) are useful in preventing and treating various liver diseases such as hepatitis, hepatic fibrosis, liver cirrhosis and liver cancer.

公开(公告)号：EP1163910A4

公开(公告)日：2003-11-12

申请号：EP00909782

申请日：2000-03-21

申请人： MITSUBISHI PHARMA CORP

发明人： IIZUKA KUNIHIKO ,  DOBASHI KUNIO ,  UEHATA MASAYOSHI

IPC分类号： A61K31/00 ,  A61K31/34 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/443 ,  A61K31/445 ,  A61K31/4525 ,  A61K31/50 ,  A61K31/501 ,  A61P11/00 ,  A61K45/00

CPC分类号： A61K31/501 ,  A61K31/00 ,  A61K31/34 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/443 ,  A61K31/445 ,  A61K31/4525 ,  A61K31/50

摘要： An agent for the prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided.